GPX4 expression is notably elevated in resistant tumor phenotypes, including cisplatin-resistant oral squamous cell carcinoma (OSCC) and recurrent nasopharyngeal carcinoma (NPC) [22,45]. Here, GPX4 is linked to neoplasm.